천식 치료 시장 : 세계 산업 규모, 점유율, 동향, 기회, 예측 - 약물 종류별, 투여 방법별, 유통 채널별, 지역별, 경쟁별(2020-2030년)

Asthma Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Class, By Mode of Administration, By Distribution Channel, By Region and Competition, 2020-2030F

US $ 4,500 ￦ 6,279,000

Unprintable PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며, 텍스트의 Copy&Paste도 불가능합니다.

US $ 5,500 ￦ 7,674,000

PDF and Excel (Multi-User License)

PDF 및 Excel 보고서를 기업의 팀이나 기관에서 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다.

US $ 8,000 ￦ 11,163,000

PDF and Excel (Custom Research License)

PDF 및 Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다. 80시간의 애널리스트 타임이 포함되어 있고 Copy & Paste 가능한 PPT 버전도 제공됩니다. 짧은 Bespoke 리서치 프로젝트 수행에 맞는 라이선스입니다.

한글목차

천식 치료 세계 시장 규모는 2024년에 278억 4,000만 달러로 예측 기간 동안 4.58%의 CAGR로 성장하여 2030년에는 364억 7,000만 달러에 달할 것으로 예상됩니다.

천식 유병률 증가, 헬스케어 투자 증가, 첨단 치료제에 초점을 맞춘 연구 개발 이니셔티브의 확대로 시장이 확대되고 있습니다. 천식은 여전히 세계 공중보건의 큰 문제이며, 특히 미국과 같은 국가에서는 천식의 부담이 커서 효과적인 치료에 대한 큰 수요가 발생하고 있습니다. 스마트 흡입기 및 분무기와 같은 약물전달 시스템의 혁신과 생물학적 제제의 가용성 확대로 천식 관리가 크게 변화하고 있습니다. 생물학적 제제 치료는 중증 환자들을 대상으로 한 표적 중재를 통해 결과를 개선하고 입원을 줄입니다. 이러한 발전은 환자 중심의 정밀의료에 대한 관심과 함께 세계 천식 치료 시장의 지속적인 성장을 촉진할 것으로 예상됩니다.

시장 개요
예측 기간	2026-2030년
시장 규모 : 2024년	278억 4,000만 달러
시장 규모 : 2030년	364억 7,000만 달러
CAGR : 2025-2030년	4.58%
급성장 부문	온라인 약국
최대 시장	북미

시장 촉진요인

R&D 투자 증가

주요 시장 과제

첨단 치료제의 고비용

주요 시장 동향

디지털 헬스 기술 통합

목차

제1장 개요

제2장 조사 방법

제3장 주요 요약

제4장 고객의 소리

제5장 세계의 천식 치료 시장 전망

• 시장 규모 및 예측
  • 금액별
• 시장 점유율과 예측
  • 약물 종류별(단시간 작용형 β자극제(SABA), 장시간 작용형 β자극제(LABA), 흡입 코르티코스테로이드(ICS), 류코트리엔 조절제, 면역조절제, 배합약, 기타)
  • 투여 방법별(흡입기, 네블라이저, 경구제)
  • 유통 채널별(병원 약국, 소매 약국, 온라인 약국, 기타)
  • 기업별(2024)
  • 지역별
• 시장 맵

제6장 북미의 천식 치료 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 북미 : 국가별 분석
  • 미국
  • 멕시코
  • 캐나다

제7장 유럽의 천식 치료 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 유럽 : 국가별 분석
  • 프랑스
  • 독일
  • 영국
  • 이탈리아
  • 스페인

제8장 아시아태평양의 천식 치료 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 아시아태평양 : 국가별 분석
  • 중국
  • 인도
  • 한국
  • 일본
  • 호주

제9장 남미의 천식 치료 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 남미 : 국가별 분석
  • 브라질
  • 아르헨티나
  • 콜롬비아

제10장 중동 및 아프리카의 천식 치료 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 중동 및 아프리카 : 국가별 분석
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트

제11장 시장 역학

• 성장 촉진요인
• 과제

제12장 시장 동향과 발전

• 인수합병
• 제품 출시
• 최근 동향

제13장 Porter's Five Forces 분석

• 업계내 경쟁
• 신규 참여의 가능성
• 공급업체의 능력
• 고객의 능력
• 대체품의 위협

제14장 경쟁 구도

• GlaxoSmithKline, Plc
• AstraZeneca Plc
• Teva Pharmaceutical Industries Ltd.
• Boehringer Ingelheim Gmbh
• Merck & Co. Inc.
• Novartis AG
• Sanofi SA
• Roche Holding AG
• Regeneron Pharmaceutical Inc.
• Pfizer Inc.

제15장 전략적 제안

제16장 조사 회사 소개 및 면책사항

ksm

영문 목차

영문목차

The Global Asthma Treatment Market was valued at USD 27.84 billion in 2024 and is projected to reach USD 36.47 billion by 2030, growing at a CAGR of 4.58% during the forecast period. The market is expanding due to the rising prevalence of asthma, increased healthcare investment, and growing R&D initiatives focused on advanced therapeutics. Asthma remains a major public health concern globally, particularly in countries like the United States, where its burden has created significant demand for effective treatments. Technological innovations in drug delivery systems-such as smart inhalers and nebulizers-and the growing availability of biologic therapies are transforming asthma management. Biologic treatments offer targeted intervention for severe cases, improving outcomes and reducing hospitalizations. These advancements, along with the focus on patient-centric and precision medicine, are expected to drive continued growth in the global asthma treatment landscape.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 27.84 Billion
Market Size 2030	USD 36.47 Billion
CAGR 2025-2030	4.58%
Fastest Growing Segment	Online Pharmacies
Largest Market	North America

Key Market Drivers

Increasing Investment in Research and Development

Substantial investment in R&D is a key driver of innovation in the asthma treatment market. With asthma being a complex, chronic condition, pharmaceutical companies and health organizations are prioritizing the development of new drugs and therapies to meet unmet needs. In the U.S., the National Institutes of Health (NIH) allocates over USD 100 million annually for asthma research, supporting advancements in diagnostics, treatment modalities, and prevention strategies. These investments contribute to breakthroughs in biologics, combination therapies, and personalized medicine approaches that enhance treatment effectiveness and patient outcomes. Furthermore, advancements in drug delivery devices and digital health solutions are improving disease monitoring and self-management.

Key Market Challenges

High Cost of Advanced Therapies

A major barrier in the global asthma treatment market is the high cost of biologic therapies used to treat severe asthma. These treatments, such as monoclonal antibodies, can cost thousands of dollars annually per patient, limiting access in low- and middle-income countries and placing strain on healthcare budgets even in developed regions. Limited insurance coverage and inconsistent reimbursement policies further exacerbate this issue, often resulting in delays or non-adherence to prescribed therapies. While biologics are effective, the associated costs can hinder widespread adoption, and addressing this financial barrier will be crucial for equitable access to advanced asthma treatments.

Key Market Trends

Integration of Digital Health Technologies

The increasing integration of digital technologies is reshaping asthma management. Tools such as mobile apps, wearable devices, and smart inhalers are enabling patients to track symptoms, monitor environmental triggers, and ensure medication adherence in real time. Smart inhalers equipped with sensors send usage data to connected devices, allowing both patients and healthcare providers to assess therapy effectiveness and make timely adjustments. These innovations support personalized asthma management, reduce flare-ups, and decrease hospital visits. As healthcare moves toward remote monitoring and data-driven decision-making, digital health technologies are expected to play a central role in asthma care delivery.

Key Market Players

• GlaxoSmithKline, Plc
• AstraZeneca Plc
• Teva Pharmaceutical Industries Ltd.
• Boehringer Ingelheim GmbH
• Merck & Co. Inc.
• Novartis AG
• Sanofi SA
• Roche Holding AG
• Regeneron Pharmaceutical Inc.
• Pfizer Inc.

Report Scope:

In this report, the Global Asthma Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Asthma Treatment Market, By Drug Class:

• Short-Acting Beta-Agonists (SABA)
• Long-Acting Beta-Agonists (LABA)
• Inhaled Corticosteroids (ICS)
• Leukotriene Modifiers
• Immunomodulators
• Combination Drugs
• Others

Asthma Treatment Market, By Mode of Administration:

• Inhalers
• Nebulizers
• Oral Medications

Asthma Treatment Market, By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others

Asthma Treatment Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Asthma Treatment Market.

Available Customizations:

Global Asthma Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global Asthma Treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Drug Class (Short-Acting Beta-Agonists (SABA), Long-Acting Beta-Agonists (LABA), Inhaled Corticosteroids (ICS), Leukotriene Modifiers, Immunomodulators, Combination Drugs, Others)
  • 5.2.2. By Mode of Administration (Inhalers, Nebulizers, Oral Medications)
  • 5.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others)
  • 5.2.4. By Company (2024)
  • 5.2.5. By Region
• 5.3. Market Map

6. North America Asthma Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Drug Class
  • 6.2.2. By Mode of Administration
  • 6.2.3. By Distribution Channel
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Asthma Treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Drug Class
      • 6.3.1.2.2. By Mode of Administration
      • 6.3.1.2.3. By Distribution Channel
  • 6.3.2. Mexico Asthma Treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Drug Class
      • 6.3.2.2.2. By Mode of Administration
      • 6.3.2.2.3. By Distribution Channel
  • 6.3.3. Canada Asthma Treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Drug Class
      • 6.3.3.2.2. By Mode of Administration
      • 6.3.3.2.3. By Distribution Channel

7. Europe Asthma Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drug Class
  • 7.2.2. By Mode of Administration
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Asthma Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Drug Class
      • 7.3.1.2.2. By Mode of Administration
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. Germany Asthma Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Drug Class
      • 7.3.2.2.2. By Mode of Administration
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. United Kingdom Asthma Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Drug Class
      • 7.3.3.2.2. By Mode of Administration
      • 7.3.3.2.3. By Distribution Channel
  • 7.3.4. Italy Asthma Treatment Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Drug Class
      • 7.3.4.2.2. By Mode of Administration
      • 7.3.4.2.3. By Distribution Channel
  • 7.3.5. Spain Asthma Treatment Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Drug Class
      • 7.3.5.2.2. By Mode of Administration
      • 7.3.5.2.3. By Distribution Channel

8. Asia-Pacific Asthma Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Drug Class
  • 8.2.2. By Mode of Administration
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Asthma Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Drug Class
      • 8.3.1.2.2. By Mode of Administration
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. India Asthma Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Drug Class
      • 8.3.2.2.2. By Mode of Administration
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. South Korea Asthma Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Drug Class
      • 8.3.3.2.2. By Mode of Administration
      • 8.3.3.2.3. By Distribution Channel
  • 8.3.4. Japan Asthma Treatment Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Drug Class
      • 8.3.4.2.2. By Mode of Administration
      • 8.3.4.2.3. By Distribution Channel
  • 8.3.5. Australia Asthma Treatment Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Drug Class
      • 8.3.5.2.2. By Mode of Administration
      • 8.3.5.2.3. By Distribution Channel

9. South America Asthma Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Drug Class
  • 9.2.2. By Mode of Administration
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Asthma Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Drug Class
      • 9.3.1.2.2. By Mode of Administration
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. Argentina Asthma Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Drug Class
      • 9.3.2.2.2. By Mode of Administration
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. Colombia Asthma Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Drug Class
      • 9.3.3.2.2. By Mode of Administration
      • 9.3.3.2.3. By Distribution Channel

10. Middle East and Africa Asthma Treatment Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Drug Class
  • 10.2.2. By Mode of Administration
  • 10.2.3. By Distribution Channel
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Asthma Treatment Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Drug Class
      • 10.3.1.2.2. By Mode of Administration
      • 10.3.1.2.3. By Distribution Channel
  • 10.3.2. Saudi Arabia Asthma Treatment Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Drug Class
      • 10.3.2.2.2. By Mode of Administration
      • 10.3.2.2.3. By Distribution Channel
  • 10.3.3. UAE Asthma Treatment Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Drug Class
      • 10.3.3.2.2. By Mode of Administration
      • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Porters Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Products

14. Competitive Landscape

• 14.1. GlaxoSmithKline, Plc
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Financials (As Reported)
  • 14.1.5. Recent Developments
  • 14.1.6. Key Personnel Details
  • 14.1.7. SWOT Analysis
• 14.2. AstraZeneca Plc
• 14.3. Teva Pharmaceutical Industries Ltd.
• 14.4. Boehringer Ingelheim Gmbh
• 14.5. Merck & Co. Inc.
• 14.6. Novartis AG
• 14.7. Sanofi SA
• 14.8. Roche Holding AG
• 14.9. Regeneron Pharmaceutical Inc.
• 14.10. Pfizer Inc.

15. Strategic Recommendations

16. About Us & Disclaimer

관련자료